Document is current
Any future updates will be listed below
-
Authors
Doberstein, Kai https://orcid.org/0000-0002-9114-9913
Panther, Johannes
Hahnen, Eric
Richters, Lisa https://orcid.org/0000-0002-9233-5291
Schouten, Philip C.
Harter, Philipp
Heitz, Florian
Kommoss, Stefan
Berlit, Sebastian
Tuschy, Benjamin
Sütterlin, Marc
Marmé, Frederik https://orcid.org/0000-0002-6591-3367
- License Information
-
More Information
Article History
Received: 16 December 2024
Accepted: 3 September 2025
First Online: 1 October 2025
Competing interests
: E.H. declares affiliations in various capacities with AstraZeneca, Roche, Tesaro, GSK, Clovis, amedes, ZaiLab, MSD, Immunogen, and AbbVie. P.C.S. declares employment by an AstraZeneca partner, as well as engagement in contract pathology work unrelated to the topic of the paper. Additionally, P.C.S. is a named inventor on the patent application “Methods for assessing homologous recombination deficiency in ovarian cancer cells” (WO2023031121, international publication date: March 9, 2023). P.L. is a shareholder and co-founder of VUS diagnostics BV (trading name VUS Genetics), unrelated to this work. L.R. received a travel accommodation grant from AstraZeneca in 2024. These disclosures do not influence the objectivity or conclusions of this work. The other authors declare no competing interests.
